Analgesic nephropathy historical perspective

Revision as of 06:12, 8 July 2020 by ShakibaHassanzadeh (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Analgesic nephropathy Microchapters


Patient Information


Historical Perspective


Differentiating Analgesic nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings



Medical Therapy

Future or Investigational Therapies

Case Studies

Case #1

Analgesic nephropathy historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Analgesic nephropathy historical perspective

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Analgesic nephropathy historical perspective

CDC on Analgesic nephropathy historical perspective

Analgesic nephropathy historical perspective in the news

Blogs on Analgesic nephropathy historical perspective

Directions to Hospitals Treating Analgesic nephropathy

Risk calculators and risk factors for Analgesic nephropathy historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]


In 1953, the association between analgesic drugs and chronic renal disease was first reported in German. In 1977, Australia was first to legally ban phenacetin. In 1983, phenacetin was withdrawn from the US markets.

Historical Perspective


  1. 1.0 1.1 Foye, William (2008). Foye's principles of medicinal chemistry. Philadelphia: Lippincott Williams & Wilkins. ISBN 978-0-7817-6879-5. OCLC 145942325.
  2. Spühler O, Zollinger HU (1953). "Die chronisch-interstitielle Nephritis". Z Klin Med (in German). 151 (1): 1–50. PMID 13137299.
  3. Michielsen P, de Schepper P (2001). "Trends of analgesic nephropathy in two high-endemic regions with different legislation". J. Am. Soc. Nephrol. 12 (3): 550–6. PMID 11181803. Unknown parameter |month= ignored (help)
  4. 4.0 4.1 "Some pharmaceutical drugs". IARC Monogr Eval Carcinog Risk Chem Hum. 24: 1–337. 1980. PMID 6937434.
  5. "List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule". Fed Regist. 64 (44): 10944–7. 1999. PMID 10557618.

Template:WH Template:WS